Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating ...

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Bank of America from $29.00 to $31.00 in a report issued on Tuesday,Benzinga reports. Bank of America currently has a ...

Ratings for Travere Therapeutics (NASDAQ:TVTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting ...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares.The company recently presented ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees ...